Immunic, Inc. filings document SEC reporting for a Nasdaq-listed biotechnology company developing oral therapies for neurologic disease. Recent Form 8-K reports cover financial results and corporate updates, Nasdaq minimum bid price compliance, stockholder-approved charter amendments, and the reverse stock split affecting its common stock.
Governance disclosures include director and officer appointments, executive compensation arrangements, special-meeting voting results, and definitive proxy materials. The filings also describe registered common stock, capital-structure changes, financing and clinical-program updates, and formal governance and shareholder voting subjects tied to Immunic's late-stage development model.
IMMUNIC, INC. director Jon Congleton received a grant of stock options covering 25,370 shares of common stock at an exercise price of $14.80 per share. The option vests in monthly installments over one year from the grant date and expires on July 5, 2036. Following this grant, Congleton holds 25,370 options directly, with no accompanying share purchases or sales reported.
Immunic, Inc. reported a board change linked to retirement plans. On June 29, 2026, director Tamar Howson resigned from the Board and its Compensation Committee as she transitions into retirement. The company states her resignation did not result from any disagreement over operations, policies, or practices.
Following a recommendation from the Nominating and Corporate Governance Committee, the Board appointed Chief Executive Officer Erik Lundgren as a Class II director, effective July 5, 2026. He will serve until the 2028 annual meeting of stockholders. Lundgren will receive no additional compensation for board service, has not joined any board committee, and aside from his existing employment agreement and CEO compensation, the filing notes no related-party transactions requiring disclosure.
IMMUNIC, INC. director Jon Congleton received a grant of stock options covering 50,740 shares of common stock. The options have an exercise price of $10.90 per share and were conditionally approved by the Board on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan, which was obtained at the 2026 Annual Meeting on June 29, 2026. The options vest in 36 equal monthly installments from March 27, 2026, and expire on March 27, 2036, leaving Congleton with 50,740 options following this grant.
IMMUNIC, INC. director Simona Skerjanec received a grant of stock options covering 25,370 shares of common stock. The options carry an exercise price of $10.90 per share and are fully vested as of March 27, 2026. The grant was conditionally approved by the board on March 27, 2026 and became effective after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting held on June 29, 2026. Following this grant, Skerjanec holds 25,370 stock options directly.
IMMUNIC, INC. director Richard Alan Rudick received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $10.90 per share and expire on March 27, 2036.
The Board conditionally approved the grant on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan, which was obtained at the June 29, 2026 annual meeting. The option was fully vested as of March 27, 2026, and Rudick now holds options for 25,370 shares directly.
IMMUNIC, INC. director Tamar D. Howson received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $10.90 per share, are fully vested as of March 27, 2026, and expire on March 27, 2036. The grant was conditionally approved by the Board on March 27, 2026, subject to stockholder approval of an amendment to the company’s 2019 Omnibus Equity Incentive Plan, which was obtained at the 2026 Annual Meeting of Stockholders held on June 29, 2026.
IMMUNIC, INC. director Joerg Neermann reported a grant of stock options on common stock. He received options on 25,370 shares at an exercise price of $10.90 per share, all of which are fully vested as of March 27, 2026.
The options were conditionally approved by the board on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan. That approval was obtained at the 2026 Annual Meeting of Stockholders on June 29, 2026. Following the grant, this option position totals 25,370 shares and there are no remaining derivative holdings shown beyond this grant.
IMMUNIC, INC. director Barclay A. Phillips received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $10.90 per share and are fully vested as of March 27, 2026. The grant was conditionally approved by the Board on March 27, 2026 and became effective after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting held on June 29, 2026. Following this award, Phillips holds options on 25,370 shares directly.
IMMUNIC, INC. reported that President and COO Jason Tardio received a grant of stock options covering 253,000 shares of common stock. The options have an exercise price of $11.60 per share and expire on April 2, 2036. The grant was conditionally approved by the board and became effective after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting of Stockholders held on June 29, 2026. The options vest 25% on April 2, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, aligning the executive’s compensation with longer-term company performance.
IMMUNIC, INC. Chief Financial Officer Glenn Whaley received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $11.60 per share and expire on April 2, 2036. The award was approved in connection with an amendment to the company’s 2019 Omnibus Equity Incentive Plan that stockholders approved at the 2026 Annual Meeting of Stockholders held on June 29, 2026. The underlying shares vest 25% on April 2, 2027, with the remaining portion vesting in equal monthly installments over the next 36 months. Following this grant, Whaley holds 120,000 options directly.